Skip to main content

In Brief This Week: Caprotec; Cytoo; Kreatech Diagnostics; Toray Industries; and WaferGen Biosystems

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said this week that it has opened its US subsidiary, Caprotec, which is based in Burlington, Mass. The new subsidiary will be responsible for North American sales, marketing, and support for the Capture Compound Mass Spectrometry technology and related products.

The firm hired Christian Jurinke to serve as president of the US subsidiary, and it has inked a sales and marketing collaboration in North America with Genovative Solutions, it said.

French high-content cell analysis firm Cytoo has opened a wholly-owned US subsidiary and named William Sharp as its president and CEO. Sharp also becomes a member of the board of directors of Cytoo. The new subsidiary, which shares the parent firm's name, is based in Framingham, Mass.

Amsterdam, The Netherlands-based Kreatech Diagnostics said this week that it has completed a €2 million financing round, with investments from LSP and Alafi Capital. The round of financing was the first priority of CEO Kees Moonen, who was named to that position just two months ago.

Japanese firm Toray Industries has launched an award program, under which researchers can apply to receive free 3D-Gene microarray analysis services from the firm. The firm said that researchers seeking gene expression analysis can apply to receive the services from Toray along with a grant of $2,000 to cover sample preparation costs. Toray said that it will accept applications until Dec. 10, 2009.

WaferGen Biosystems has moved into a new facility in advance of the launch of a new service offering based on the firm's SmartChip Real-Time PCR System. The company intends to make the new service available to a few select customers in December, with a full roll-out in the first quarter of 2010.

WaferGen said that it will offer universities, pharmaceutical companies, and diagnostic firms services that utilize pathway-specific gene panels to discover and validate new biomarkers. It expects also to launch a new miRNA expression panel early next year.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.